1Phelps ME. PET: The merging of biolory and imaging into molecular imaging. J Nucl Med,2000,41:661 - 681.
2Setoain FJ,Pons F,Herranz R,et al. 67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma.Nucl Med Commun,1997 ,18 :405 -411.
3Schomacker K, Schicha H. Use of myocardial imaging agent for tumor diagnosis a success story? Eur J Nucl Med ,2000 ,27 :1845 -1863.
4Taillefer R, Robidoux A, Lambert R, et al. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med, 1995,36:1758 - 1765.
5Soderlund V ,Jonsson C, Bauer HCF ,et al. Comparison of technetium99m-MIBI and tochnetium-99m-tetrofosmin uptake by musculoskeletal scaroomas. J Nucl Med, 1997,38:682 - 686.
6Wang Rongfu, Zhang Chunli, Yu Lizhang, et al. Clinical Application of Radioimmunoimaging with 99 mTc-BDI - 1 in the Diagnosis of Bladder Cancer. Chin Med J,2000,113:396 - 399.
2Shung-Shung S, Tih-Fang H, Shih-chuan T, et al. Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results [J]. Cancer Lett, 2000, 153(1-2):95-100.
3Del-Vecchio S, Ciarmiello A, Pace L, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients[J]. J Nucl Med, 1997, 38(9):1348-1351.
4Del-Vecchio S, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistance (MDB1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients[J]. Eur J Nucl Med, 1997, 24(2):150-159.
5Kostakoglu L, Kirath P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer[J]. J Nucl Med, 1998, 39(2):228-234.
6Andrews DW, Dss R, Kim S, et al. Technetium-MIBI as a glioma imaging agent for the assessment of multidrug resistance[J]. Neurosurgery, 1997, 40(6): 1323-1332.
7Kapucu L, Akyüz C, Varal G, et al. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi[J]. J Nucl Med, 1997, 38 (2): 243-247.
8Gruber A, Arestrm I, Xu D, et al. Multidrug resistance phenotype in leukaemia cells from patients with acute myelocytie leukaemia can be detected with ~(99)Tc~m-MIBI[J]. Br J Cancer, 1998, 77(11): 1732-1736.
9Kostakoglu L, Guc D, Canpinar H, et al. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy[J]. J Nucl Med, 1998, 39(7): 1191-1197.
10Leitha T, Glaser C, Lang S. Is early sestamibi imaging in head and neck cancer affected by MDR status, P53 expression, or cell proliferation ?[J]. Nucl Med Biol, 1998, 25(6): 539-541.